Moupali Das-Douglas, MD, MPH

Email Moupali
(415) 437-4666

3333 California Street
San Francisco, CA 94104

Visit CTSI Profile

  • Assistant Clinical Professor, UCSF School of Medicine

Biography

Research Interests:
Communicable Disease Prevention and Control, including HIV/AIDS and Chronic Hepatitis, Outbreak Investigation, Applied Epidemiology and Enhanced Surveillance, such as Community Viral Load, to Evaluate Multi-level HIV Prevention Interventions, Implementation Science and Operations Research, Syndemics, Data Systems Integration, Public Health Continuous Quality Improvement, Socio-structural Determinants of Health, Structural and Systems Change, Public Health Leadership and Policy Advocacy, Behavioral and Pharmacologic Treatment of Substance Use as HIV Prevention, HIV Medication Adherence, Engagement and Retention in Care, Health and Human Rights, Health Policy and Legislative Advocacy, International Health and Tropical Medicine, and Community-Based Care of HIV and TB in Resource-Poor Settings.

Education and Training:
- A.B. cum laude, Biochemical Sciences. Harvard College, Cambridge, MA, 1992-1996
- Resident, Department of Internal Medicine. Columbia University Medical Center, New York, NY, 2001-2004
- Fellow, Infectious Diseases, University of California, San Francisco, 2005-2007
- Fellow, Center for AIDS Prevention Studies, University of California, San Francisco, 2006-2007

Displaying 1 - 32 of 32

  1. Post FA, Tebas P, Clarke A, Cotte L, Short WR, Abram ME, Jiang S, Cheng A, Das M, Fordyce MW. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2017 Feb 01; 74(2):180-184. View on Pubmed
  2. Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C, Oka S, Cheng A, Garner W, Fordyce M, Das M, McCallister S. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr. 2016 Nov 1; 73(3):294-298. View on Pubmed
  3. Huhn GD, Tebas P, Gallant J, Wilkin T, Cheng A, Yan M, Zhong L, Callebaut C, Custodio JM, Fordyce MW, Das M, McCallister S. A Randomized , Open-label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide plus Darunavir in Treatment-Experienced HIV-1 Infected Adults. J Acquir Immune Defic Syndr. 2016 Oct 06. View on Pubmed
  4. Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, Zhong L, Callebaut C, Das M, Fordyce M. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr. 2016 May 1; 72(1):58-64. View on Pubmed
  5. Hernández D, Feaster DJ, Gooden L, Douaihy A, Mandler R, Erickson SJ, Kyle T, Haynes L, Schwartz R, Das M, Metsch L. Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients. AIDS Behav. 2016 Jan; 20(1):204-14. View on Pubmed
  6. Mills A, Crofoot G, McDonald C, Shalit P, Flamm JA, Gathe J, Scribner A, Shamblaw D, Saag M, Cao H, Martin H, Das M, Thomas A, Liu HC, Yan M, Callebaut C, Custodio J, Cheng A, McCallister S. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2015 Aug 1; 69(4):439-45. View on Pubmed
  7. Das M, Kim NJ. Using Twitter to survey alcohol use in the San Francisco Bay Area. Epidemiology. 2015 Jul; 26(4):e39-40. View on Pubmed
  8. Coffin PO, Santos GM, Colfax G, Das M, Matheson T, DeMicco E, Dilley J, Vittinghoff E, Raiford JL, Carry M, Herbst JH. Adapted personalized cognitive counseling for episodic substance-using men who have sex with men: a randomized controlled trial. AIDS Behav. 2014 Jul; 18(7):1390-400. View on Pubmed
  9. Knight KR, Das M, DeMicco E, Raiford JL, Matheson T, Shook A, Antunez E, Santos GM, Dadasovich R, Dilley JW, Colfax GN, Herbst JH. A roadmap for adapting an evidence-based HIV prevention intervention: personal cognitive counseling (PCC) for episodic substance-using men who have sex with men. Prev Sci. 2014 Jun; 15(3):364-75. View on Pubmed
  10. Santos GM, Coffin PO, Vittinghoff E, DeMicco E, Das M, Matheson T, Raiford JL, Carry M, Colfax G, Herbst JH, Dilley JW. Substance use and drinking outcomes in Personalized Cognitive Counseling randomized trial for episodic substance-using men who have sex with men. Drug Alcohol Depend. 2014 May 1; 138:234-9. View on Pubmed
  11. Das M, Christopoulos KA, Geckeler D, Huriaux E, Cohen SE, Philip S, Shade S, Moss NJ, Morin SF, Charlebois ED. Linkage to HIV care in San Francisco: implications of measure selection. J Acquir Immune Defic Syndr. 2013 Nov 1; 64 Suppl 1:S27-32. View on Pubmed
  12. Metsch LR, Feaster DJ, Gooden L, Schackman BR, Matheson T, Das M, Golden MR, Huffaker S, Haynes LF, Tross S, Malotte CK, Douaihy A, Korthuis PT, Duffus WA, Henn S, Bolan R, Philip SS, Castro JG, Castellon PC, McLaughlin G, Mandler RN, Branson B, Colfax GN. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA. 2013 Oct 23; 310(16):1701-10. View on Pubmed
  13. Das M. Beyond measuring what matters to managing what matters: improving public health quality and accountability in the U.S. HIV epidemic response. Public Health Rep. 2013 Sep-Oct; 128(5):360-3. View on Pubmed
  14. Santos GM, Coffin PO, Das M, Matheson T, DeMicco E, Raiford JL, Vittinghoff E, Dilley JW, Colfax G, Herbst JH. Dose-response associations between number and frequency of substance use and high-risk sexual behaviors among HIV-negative substance-using men who have sex with men (SUMSM) in San Francisco. J Acquir Immune Defic Syndr. 2013 Aug 1; 63(4):540-4. View on Pubmed
  15. Das M, Raymond HF, Chu P, Nieves-Rivera I, Pandori M, Louie B, Rauch L, Scheer S, Vittinghoff E, McFarland W. Measuring the unknown: calculating community viral load among HIV-infected MSM unaware of their HIV status in San Francisco from National HIV Behavioral Surveillance, 2004-2011. J Acquir Immune Defic Syndr. 2013 Jun 1; 63(2):e84-6. View on Pubmed
  16. Coffin PO, Santos GM, Das M, Santos DM, Huffaker S, Matheson T, Gasper J, Vittinghoff E, Colfax GN. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Apr; 108(4):751-61. View on Pubmed
  17. Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, Tross S, Kyle T, Gallup D, Kosinski AS, Douaihy A, Schackman BR, Das M, Lindblad R, Erickson S, Korthuis PT, Martino S, Sorensen JL, Szapocznik J, Walensky R, Branson B, Colfax GN. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012 Jun; 102(6):1160-7. View on Pubmed
  18. Volberding PA, Aidala AA, Celentano DD, Das M, DeGruttola VG, del Rio C, Forstein M, Grasso C, Houser S, Kates J, Martin EG, Mayer KH, Mays VM, Pryor DP, Vermund SH, Wilcox AB, Wirth D. Monitoring HIV Care in the United States: Indicators and Data Systems. The Institute of Medicine Committee to Review Data Systems for Monitoring HIV Care. 2012. View on Pubmed
  19. Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S, Wiest K, Douaihy A, Mandler RN, Sorensen JL, Colfax G, McCarty D, Cohen SE, Penn PE, Lape D, Metsch LR. Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness. Addict Behav. 2012 Apr; 37(4):552-5. View on Pubmed
  20. Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, Shoptaw S, Vittinghoff E. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011 Nov; 68(11):1168-75. View on Pubmed
  21. Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, Simao M, Hankins C, Schwartlander B, Ridzon R, Bazin B, Williams B, Lo YR, McClure C, Montaner J, Hirnschall G. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res. 2011 Sep; 9(6):446-69. View on Pubmed
  22. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis. 2011 Apr 15; 52(8):1046-9. View on Pubmed
  23. Santos GM, Das M, Colfax GN. Interventions for non-injection substance use among US men who have sex with men: what is needed. AIDS Behav. 2011 Apr; 15 Suppl 1:S51-6. View on Pubmed
  24. Christopoulos KA, Das M, Colfax GN. Linkage and retention in HIV care among men who have sex with men in the United States. Clin Infect Dis. 2011 Jan 15; 52 Suppl 2:S214-22. View on Pubmed
  25. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, Colfax GN. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010; 5(6):e11068. View on Pubmed
  26. Das M, Santos D, Matheson T, Santos GM, Chu P, Vittinghoff E, Shoptaw S, Colfax GN. Feasibility and acceptability of a phase II randomized pharmacologic intervention for methamphetamine dependence in high-risk men who have sex with men. AIDS. 2010 Apr 24; 24(7):991-1000. View on Pubmed
  27. Mansergh G, Flores S, Koblin B, Hudson S, McKirnan D, Colfax GN. Alcohol and drug use in the context of anal sex and other factors associated with sexually transmitted infections: results from a multi-city study of high-risk men who have sex with men in the USA. Sex Transm Infect. 2008 Nov; 84(6):509-11. View on Pubmed
  28. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, Bangsberg DR. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008; 3(7):e2783.
  29. Das-Douglas M, Zetola NM, Klausner JD, Colfax GN. Written informed consent and HIV testing rates: the San Francisco experience. Am J Public Health. 2008 Sep; 98(9):1544-5; author reply 1545.
  30. Das-Douglas M, Riley ED, Ragland K, Guzman D, Clark R, Kushel MB, Bangsberg DR. Implementation of the Medicare Part D prescription drug benefit is associated with antiretroviral therapy interruptions. AIDS Behav. 2009 Feb; 13(1):1-9.
  31. Das-Douglas M, Colfax G, Moss AR, Bangsberg DR, Hahn JA. Tripling of methamphetamine/amphetamine use among homeless and marginally housed persons, 1996-2003. J Urban Health. 2008 Mar; 85(2):239-49.
  32. Frieden TR, Das-Douglas M, Kellerman SE, Henning KJ. Applying public health principles to the HIV epidemic. N Engl J Med. 2005 Dec 1; 353(22):2397-402.